Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a Decade

FDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer.

Cancer Currents: An NCI Cancer Research Blog